Ozempic Vs Trulicity - Guide | Cured Pharmacy

Ozempic Vs Trulicity

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

£145.00UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 16 June 2026

Last Updated: 12 August 2026

If you have been researching GLP-1 receptor agonist medications, you have likely come across both Ozempic and Trulicity as popular options for managing type 2 diabetes and, increasingly, supporting weight loss. Both are injectable medications that work by mimicking a natural gut hormone called GLP-1, but there are meaningful differences between them that could influence which one is better suited to your individual needs. Understanding those differences clearly can help you have a more informed conversation with your prescriber and feel more confident about your treatment path.

Quick Summary

Both Ozempic (semaglutide) and Trulicity (dulaglutide) are once-weekly GLP-1 receptor agonist injections approved primarily for type 2 diabetes, with Ozempic also being widely used off-label and in clinical practice for weight management in the UK. While they share a similar mechanism of action, Ozempic generally delivers greater HbA1c reductions and more significant weight loss at higher doses.

  • Ozempic contains semaglutide; Trulicity contains dulaglutide — both are GLP-1 receptor agonists
  • Ozempic is associated with greater average weight loss (up to 6–7% body weight) compared to Trulicity (2–3%)
  • Both are injected once weekly, but their pen devices and dose escalation schedules differ
  • Ozempic has stronger cardiovascular outcome data, particularly the SUSTAIN-6 trial
  • Neither is licensed for weight loss alone in the UK — Wegovy (higher-dose semaglutide) and Mounjaro (tirzepatide) hold those specific licences

GLP-1 Medication Comparison Tool

Answer three quick questions to see which weekly injection may suit your goals better. This tool is for information only and does not replace medical advice.

1. What is your primary goal?

Table of Contents

  1. What Are Ozempic and Trulicity?
  2. How Do They Work in the Body?
  3. Ozempic vs Trulicity: Effectiveness for Blood Sugar and Weight Loss
  4. Dosing Schedules and Pen Devices Compared
  5. Side Effects: What to Expect from Each Medication
  6. Cardiovascular Benefits and Safety Data
  7. Full Side-by-Side Comparison Table
  8. Are There Better Alternatives in 2026?
  9. Key Takeaways
  10. When to Seek Professional Advice
  11. Scientific References
  12. Frequently Asked Questions

What Are Ozempic and Trulicity?

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk and approved in the UK for adults with type 2 diabetes. It is administered as a once-weekly subcutaneous injection and has gained enormous public attention in recent years partly due to its pronounced effect on appetite and body weight. Trulicity, on the other hand, is the brand name for dulaglutide, manufactured by Eli Lilly and approved across the same indication. Choosing between Ozempic vs Trulicity often comes down to subtle but clinically important distinctions.

Both medications belong to the same drug class and are prescribed under similar NHS and private pathways in the UK. However, they are distinct molecular compounds with differing half-lives, binding affinities, and dose ranges. Ozempic is available in 0.5mg, 1mg, and 2mg doses, while Trulicity ranges from 0.75mg up to 4.5mg per week. If you are exploring weight loss aids and wondering whether injectable GLP-1 therapy is the right next step, understanding these two medications is a solid starting point.

  • Ozempic = semaglutide (Novo Nordisk) | Trulicity = dulaglutide (Eli Lilly)
  • Both approved for type 2 diabetes; neither is UK-licensed specifically for weight loss alone
  • Both are once-weekly subcutaneous injections — no daily dosing required
  • Available via NHS prescription or private prescription in the UK

How Do They Work in the Body?

GLP-1 (glucagon-like peptide-1) is a hormone naturally released in the gut after eating. It stimulates the pancreas to produce insulin in response to rising blood glucose, suppresses glucagon secretion (which would otherwise raise blood sugar), slows gastric emptying, and signals the brain's satiety centres to reduce appetite. Both Ozempic and Trulicity mimic this hormone's action, which is why they help control blood sugar and often lead to weight reduction as a secondary benefit. When comparing Ozempic vs Trulicity in terms of mechanism, both are effective GLP-1 mimetics, but semaglutide binds to the GLP-1 receptor with a slightly higher affinity and has a longer half-life of approximately one week, compared to dulaglutide's five-day half-life.

This pharmacological difference has real-world implications. The longer and more potent receptor engagement of semaglutide translates into greater reductions in HbA1c and more pronounced appetite suppression in head-to-head trials. Trulicity's mechanism is equally valid but produces a somewhat more modest effect at equivalent clinical doses. Both drugs are degradation-resistant analogues that have been structurally modified to resist the enzyme DPP-4, which normally breaks down natural GLP-1 very rapidly after release.

  • Both work by mimicking the gut hormone GLP-1 after meals
  • Stimulate insulin release, suppress glucagon, slow digestion, and reduce appetite
  • Semaglutide has a longer half-life and higher receptor binding affinity
  • Neither causes low blood sugar (hypoglycaemia) on their own — only in combination with insulin or sulphonylureas

Ozempic vs Trulicity: Effectiveness for Blood Sugar and Weight Loss

When it comes to clinical outcomes, the data firmly favours Ozempic for both HbA1c reduction and weight loss. The SUSTAIN trial programme for semaglutide and the AWARD trial programme for dulaglutide have both produced extensive data, and direct head-to-head comparisons confirm semaglutide's edge. In the SUSTAIN-7 trial, which directly compared the two medications, semaglutide 1mg reduced HbA1c by approximately 1.5% compared to 1.1% with dulaglutide 1.5mg. Body weight reduction was also more pronounced: participants lost around 5.9kg on semaglutide versus 2.3kg on dulaglutide over 40 weeks.

For anyone who has struggled with weight alongside type 2 diabetes, this difference is significant. Ozempic vs Trulicity comparisons consistently show semaglutide producing approximately 6–7% total body weight loss at its higher doses, while dulaglutide typically achieves 2–3%. If weight loss is a secondary goal alongside diabetes management, many prescribers now default to semaglutide for this reason. For those who want even greater weight reduction with a dedicated weight loss licence, Mounjaro (tirzepatide) injections offer the most potent option currently available in the UK.

  • Semaglutide reduces HbA1c by ~1.5% vs ~1.1% for dulaglutide (SUSTAIN-7)
  • Weight loss: ~5.9kg (Ozempic 1mg) vs ~2.3kg (Trulicity 1.5mg) over 40 weeks
  • Both achieve clinically meaningful HbA1c reductions compared to placebo
  • Ozempic's 2mg dose provides even greater weight reduction, closer to 6–7% total body weight
  • Trulicity remains a valuable option for patients who cannot tolerate higher-dose semaglutide

Dosing Schedules and Pen Devices Compared

One of the most practical considerations when evaluating Ozempic vs Trulicity is how each medication is delivered. Ozempic comes in a reusable multi-dose pen that requires the user to attach a new needle before each injection. It is available in three pen strengths: 0.25mg/0.5mg, 1mg, and 2mg. The dose escalation schedule starts at 0.25mg weekly for four weeks, then moves to 0.5mg, and can be increased further to 1mg or 2mg based on response and tolerability. This gradual escalation is designed to reduce gastrointestinal side effects during the early weeks of treatment.

Trulicity uses a single-use auto-injector pen that is arguably simpler to operate — the needle is hidden, which many injection-anxious patients find reassuring. Each pen is pre-filled and ready to use, requiring no needle attachment. The starting dose is 0.75mg weekly, increasing to 1.5mg, then optionally to 3mg, and finally to a maximum of 4.5mg. Many patients who are new to injectable therapies find Trulicity's pen design less intimidating, and this practical factor can influence adherence. If you are currently using oral weight loss support and considering stepping up to an injectable, the device type matters more than most people realise.

  • Ozempic: reusable multi-dose pen, needle attachment required, doses from 0.25mg to 2mg
  • Trulicity: single-use auto-injector, no visible needle, doses from 0.75mg to 4.5mg
  • Both injected once weekly, ideally on the same day each week
  • Both can be injected into the abdomen, thigh, or upper arm
  • Trulicity may be preferred for needle-anxious patients due to its concealed needle design

Side Effects: What to Expect from Each Medication

Both medications share a broadly similar side effect profile, which is expected given they work through the same GLP-1 receptor mechanism. Gastrointestinal effects are the most commonly reported — nausea, vomiting, diarrhoea, constipation, and abdominal discomfort affect a significant proportion of users, particularly during the dose escalation phase. For most people, these symptoms are mild to moderate and improve substantially after the first few weeks. The key pain point many patients report is not the injections themselves but the nausea during the early weeks, and knowing this is temporary makes it much easier to persevere.

In comparing Ozempic vs Trulicity specifically for side effects, studies suggest that nausea and vomiting may be slightly more common with semaglutide at higher doses, likely because of its more potent GLP-1 receptor binding. Trulicity tends to cause less pronounced gastrointestinal symptoms, which is part of why some patients prefer it despite its more modest efficacy. Serious but rare side effects for both include pancreatitis, gallbladder issues, and potential kidney function changes. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. If you experience persistent abdominal pain, you should seek medical attention promptly.

  • Most common: nausea, vomiting, diarrhoea, constipation — typically mild and transient
  • Semaglutide may cause slightly more pronounced GI effects at higher doses
  • Rare serious risks: pancreatitis, gallstones, kidney function changes
  • Both are contraindicated with a history of medullary thyroid cancer or MEN2
  • Injection site reactions are uncommon but can occur — rotate injection sites regularly
  • Neither medication alone causes hypoglycaemia in type 2 diabetes

Cardiovascular Benefits and Safety Data

One of the most compelling reasons to choose Ozempic over Trulicity for certain patients is its cardiovascular outcome data. The landmark SUSTAIN-6 trial demonstrated that semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) — including non-fatal heart attack and non-fatal stroke — by 26% compared to placebo in high-risk patients with type 2 diabetes. This was a pivotal finding that has influenced NICE guidance and prescribing decisions across the UK, particularly for patients with established cardiovascular disease.

Trulicity also has positive cardiovascular data. The REWIND trial demonstrated that dulaglutide reduced MACE risk by 12% compared to placebo over a median follow-up of 5.4 years, and importantly this benefit extended to patients who did not have pre-existing cardiovascular disease, which is a notable distinction. In a direct head-to-head context, however, semaglutide's absolute risk reduction and the statistical robustness of SUSTAIN-6 have given it a stronger reputation in this area. For patients comparing Ozempic vs Trulicity and who have a history of heart disease or stroke, most UK cardiologists and diabetologists would lean toward semaglutide. As of 2026, both drugs remain first-line options for people with type 2 diabetes who have or are at high risk of cardiovascular disease, per updated NICE guidelines.

  • Ozempic (SUSTAIN-6): 26% relative reduction in MACE vs placebo in high-risk patients
  • Trulicity (REWIND): 12% relative reduction in MACE, including lower-risk patients
  • Ozempic has stronger data for existing cardiovascular disease
  • Trulicity's REWIND data includes primary prevention population — broader applicability
  • Both are recommended by NICE for patients with type 2 diabetes and high cardiovascular risk

Full Side-by-Side Comparison Table

Feature Ozempic (Semaglutide) Trulicity (Dulaglutide)
Drug class GLP-1 receptor agonist GLP-1 receptor agonist
Manufacturer Novo Nordisk Eli Lilly
Starting dose 0.25mg once weekly 0.75mg once weekly
Maximum dose 2mg once weekly 4.5mg once weekly
HbA1c reduction ~1.5% (at 1mg) ~1.1% (at 1.5mg)
Average weight loss 5–7% body weight 2–3% body weight
Pen device Reusable, needle attachment required Single-use auto-injector, hidden needle
Injection frequency Once weekly Once weekly
Half-life ~7 days ~5 days
Cardiovascular trial SUSTAIN-6 (26% MACE reduction) REWIND (12% MACE reduction)
UK weight loss licence No (Wegovy = licensed semaglutide for weight) No
Common side effects Nausea, vomiting, diarrhoea Nausea, diarrhoea, abdominal pain
Best suited for Greater weight loss + CV risk reduction Needle-anxious patients, milder GI tolerance

Are There Better Alternatives in 2026?

While Ozempic vs Trulicity remains one of the most searched GLP-1 comparisons in the UK, it is worth knowing that the treatment landscape has expanded considerably. Wegovy (semaglutide 2.4mg) is now available in the UK with a specific licence for chronic weight management in adults with obesity or overweight with weight-related comorbidities. It uses the same active ingredient as Ozempic but at a higher dose, and it has been shown to reduce body weight by an average of 14.9% in the STEP-1 trial. This makes it significantly more effective for weight loss than either Ozempic or Trulicity.

Perhaps the most significant development in this therapeutic area is Mounjaro (tirzepatide), which is both a GLP-1 and GIP receptor agonist — a dual-action mechanism that produces even greater weight loss and HbA1c reduction than semaglutide. Clinical trial data from the SURMOUNT-1 trial showed average weight reductions of up to 22.5% at the highest dose (15mg), which is remarkable. Mounjaro received its UK licence for type 2 diabetes and weight management, and it has rapidly become the preferred option for many patients and prescribers seeking maximum efficacy. If you have already tried Alli weight loss capsules or other oral options without sufficient results, an injectable GLP-1 or GIP/GLP-1 agent may represent a meaningful step forward in your weight management journey.

For patients who are concerned about cost or who cannot access injectable medications, oral options still play a role. Fat binder sachets and other over-the-counter weight management products can complement lifestyle changes when prescription medications are not yet an option. However, the clinical evidence for GLP-1 injectables far exceeds that of any OTC alternative in terms of sustained weight loss and metabolic benefit.

  • Wegovy (semaglutide 2.4mg): licensed for weight management in the UK, ~15% body weight loss
  • Mounjaro (tirzepatide): dual GLP-1/GIP agonist, up to 22.5% weight loss in trials
  • Both Wegovy and Mounjaro require a formal obesity assessment and prescribing pathway
  • OTC weight management products remain an option for those not yet eligible for injectables
  • As of 2026, Mounjaro is widely considered the most effective licensed weight loss injection available in the UK

Key Takeaways

  • Ozempic (semaglutide) produces greater HbA1c reductions and weight loss than Trulicity (dulaglutide) in head-to-head clinical trials
  • Trulicity's simpler auto-injector pen may be a better fit for needle-anxious patients or those new to injectable therapy
  • Both medications are once-weekly injections primarily licensed for type 2 diabetes in the UK — neither holds a specific weight loss licence
  • For dedicated weight management, Wegovy and Mounjaro represent more appropriate and more effective licensed options
  • Your prescriber should take into account your cardiovascular risk, weight loss goals, tolerability preferences, and NHS eligibility before recommending either medication

When to Seek Professional Advice

If you are currently taking either Ozempic or Trulicity and experiencing persistent nausea, vomiting that prevents normal eating, severe abdominal pain, or any new symptoms that concern you, contact your GP or prescribing pharmacist promptly. Persistent upper abdominal pain that radiates to the back may occasionally indicate pancreatitis, a rare but serious complication — this requires urgent medical attention. You should also speak to a healthcare professional if you are not seeing any improvement in your blood sugar or weight after three to six months at the maximum tolerated dose, as this may indicate a need to review or change your treatment.

If you are researching these medications because you are trying to manage your weight and have a BMI of 30 or above (or 27.5 with a weight-related health condition), you may be eligible for a formal weight management assessment. At Cured Pharmacy, our UK-based prescribing pharmacists can assess your suitability for GLP-1 medications through a confidential online consultation. We also stock Mounjaro (tirzepatide), which as of 2026 remains the most clinically advanced weight loss injection available with a UK licence. Early intervention with the right medication can make a meaningful long-term difference to both metabolic health and quality of life.

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My Assessment Returning Customer? Log In to Your Account

Frequently Asked Questions

How long does it take for Ozempic or Trulicity to start working?

Both Ozempic and Trulicity begin working within the first week of injection, but meaningful blood sugar improvements and any noticeable weight changes typically take four to eight weeks. Full therapeutic effects, including significant HbA1c reduction and sustained weight loss, are generally seen after three to six months of consistent use.

Is Ozempic safe to use long term in the UK?

Ozempic is considered safe for long-term use in the UK when prescribed and monitored appropriately. Clinical trial data and post-marketing surveillance up to 2026 support its cardiovascular safety profile. Regular reviews with your prescriber are recommended to monitor kidney function, thyroid health, and any gastrointestinal side effects that may emerge over time.

Can you switch from Trulicity to Ozempic?

You can switch from Trulicity to Ozempic under the guidance of your prescriber. Switching is relatively straightforward since both are weekly GLP-1 injections, but your doctor will typically start you on a low Ozempic dose and titrate upward. A washout period is not usually required, but your blood sugar should be monitored during the transition.

What is the starting dose of Ozempic compared to Trulicity?

The starting dose of Ozempic is 0.25mg once weekly for four weeks before increasing to 0.5mg, while Trulicity starts at 0.75mg once weekly for at least four weeks before moving to 1.5mg. Ozempic offers higher maximum doses of up to 2mg, whereas Trulicity reaches a maximum of 4.5mg weekly.

Scientific References

When comparing Ozempic vs Trulicity, the evidence consistently points to semaglutide as the more potent option for both blood sugar control and weight reduction, though Trulicity remains a clinically sound and well-tolerated alternative for many patients. The right choice ultimately depends on your individual health profile, goals, and preferences — always make this decision in partnership with a qualified UK prescriber.

Back to blog